NTRK3 and neurodegenerative disease: Ligands with isoform selectivity would be desirable in neurodegenerative diseases to selectively activate TrkC-FL neuroprotection and to selectively inhibit TrkC.T1 neurotoxicity (Saragovi et al., 2019).